# US 2025/0093349 A1 · Antigens Derived from Citrullinated 14-3-3 and Uses Thereof in the Diagnosis of Rheumatoid Arthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0093349 A1
- Document ID: US20250093349A1
- Status: Published application
- Kind: A1
- Application number: 18/587,846
- Filed: 2024-02-26
- Published: 2025-03-20
- Earliest claimed: 2011-10-21
- Assignees: Augurex Life Sciences Corp.
- Applicants: Augurex Life Sciences Corp.
- Inventors: Anthony Marotta
- Web page: https://patentgrep.com/patent/US20250093349A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- C07K 14/47: from mammals
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2440/18: citrullination
- G01N 2800/105: Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.

## Claims

### Claim 1

An isolated citrullinated 14-3-3 eta protein or fragment thereof specifically recognized by anti-14-3-3 eta autoantibodies present in the serum of a patient suffering from an arthritic condition.

### Claim 2 (depends on 1)

The protein of claim 1, comprising a citrulline residue at a position selected from the group consisting of position 4, position 12, position 19, position 42, position 61, position 86 and position 227 of SEQ ID NO: 5.

### Claim 3 (depends on 1)

The protein of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-22.

### Claim 4 (depends on 1)

The protein according to claim 1, wherein said arthritic condition is rheumatoid arthritis.

### Claim 5 (depends on 2)

A composition comprising at least one citrullinated 14-3-3 eta protein according to claim 2 bound to a solid support.

### Claim 6 (depends on 1)

A kit comprising at least one citrullinated 14-3-3 eta protein according to claim 1.

### Claim 7

A method for diagnosing an arthritic condition in a subject comprising contacting a biological sample from the subject with at least one citrullinated 14-3-3 protein or fragment thereof under a condition suitable for the formation of at least one immune complex between the citrullinated 14-3-3 protein or fragment thereof and autoantibodies against the citrullinated 14-3-3 protein or fragment thereof that may be present in the biological sample; and detecting the presence of immune complexes between the citrullinated 14-3-3 protein or fragment thereof and autoantibodies against the citrullinated 14-3-3 protein or fragment thereof; wherein said presence of said immune complexes is indicative of an arthritic condition in said subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein said detecting step further comprises measuring the amount of autoantibodies against the citrullinated 14-3-3 protein or fragment thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the citrullinated 14-3-3 protein is citrullinated 14-3-3 eta.

### Claim 10 (depends on 7)

The method of claim 7, wherein the citrullinated 14-3-3 protein is a fragment of citrullinated 14-3-3 eta.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the citrullinated 14-3-3 protein or fragment thereof is detectably labeled with a label selected from the group consisting of a radioactive label, a luminescent label, and a fluorescent label, and an enzyme.

### Claim 12 (depends on 7)

The method according to claim 7, wherein the citrullinated 14-3-3 protein or fragment thereof is bound to a solid support.

### Claim 13 (depends on 7)

The method according to claim 7, wherein the autoantibodies are detected by an ELISA assay.

### Claim 14 (depends on 7)

The method according to claim 7, wherein said detection occurs by chemiluminesence.

### Claim 15 (depends on 7)

The method according to claim 7, wherein said arthritic condition is rheumatoid arthritis.

### Claim 16 (depends on 1)

An antibody directed to the citrullinated 14-3-3 protein according to claim 1, wherein the citrullinated 14-3-3 protein is specifically recognized by anti-14-3-3 eta autoantibodies present in the serum of a patient suffering from an arthritic condition.

### Claim 17 (depends on 16)

The antibody according to claim 16, wherein said antibody selectively binds the citrullinated form.

### Claim 18 (depends on 16)

A non-human host producing an antibody according to claim 16.

### Claim 19 (depends on 18)

The host of claim 18, wherein the host is a hybridoma cell line.

### Claim 20

A method for diagnosing and/or prognosing an arthritic condition in a subject comprising
contacting a biological sample from the subject with at least one antibody capable of binding selectively to a citrullinated human 14-3-3 protein or a fragment thereof under a condition suitable for the formation of at least one immune complex between the antibody and citrullinated 14-3-3 proteins that may be present in the biological sample; and
detecting the presence, degree and/or location of at least one citrulline residue within said citrullinated 14-3-3 protein,
wherein said presence, degree and/or location of said at least one citrulline residue is indicative of an arthritic condition in said subject or informative of a prognosis for said subject.
